{"id":"W2550644244","doi":"10.1136/annrheumdis-2016-eular.3359","title":"THU0140 Efficacy and Safety Analysis by Overall anti-Drug Antibody Results Up To Week 30 in Patients with Rheumatoid Arthritis Treated with Sb2 (An Infliximab Biosimilar) or Infliximab Reference Product in Phase III Study","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Biosimilar; Infliximab; Internal medicine; Methotrexate; Immunogenicity; Gastroenterology; Clinical efficacy; Safety profile; Drug; Surgery; Antibody; Adverse effect; Pharmacology; Immunology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002282769,0.001106137,0.002571416,0.0005803464,0.0003304944,0.001266429,0.0006603276,0.0009461638,0.00183785],"category_scores_gemma":[0.00161437,0.000554374,0.002456205,0.0006272711,0.000691796,0.0007620034,0.0004452025,0.001951193,0.000529696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007439389,"about_ca_system_score_gemma":0.0007151967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000486452,"about_ca_topic_score_gemma":0.0008028437,"domain_scores_codex":[0.9991474,0.0004051095,0.00006068404,0.0001526909,0.000113228,0.0001208911],"domain_scores_gemma":[0.9989421,0.0002273931,0.0003526612,0.00008628368,0.0001076352,0.0002840184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8634014,0.006150879,0.05093771,0.0007076497,0.005205151,0.0001722961,0.0001661232,0.001065612,0.02071353,0.0001774408,0.0009939682,0.05030831],"study_design_scores_gemma":[0.4133474,0.3183616,0.242851,0.0001392457,0.00905398,0.0006514564,0.0001677918,0.003373092,0.007311473,0.0005509495,0.004007119,0.000184893],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959366,0.002444296,0.0001925694,0.0001026939,0.00004695246,0.0001502704,0.0004615564,0.00002936725,0.0006356056],"genre_scores_gemma":[0.9952472,0.0008271983,0.0005959688,0.0002003801,0.00008475002,0.0002433708,0.001751696,0.0000147558,0.001034655],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002571416,"threshold_uncertainty_score":0.01207256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02680917179020043,"score_gpt":0.3187931148104403,"score_spread":0.2919839430202399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}